Pharmagreen Biotech Beta vs. Z Score
| PHBI Stock | USD 0 0.0001 5.88% |
For Pharmagreen Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pharmagreen Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pharmagreen Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pharmagreen Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pharmagreen Biotech over time as well as its relative position and ranking within its peers.
Pharmagreen |
Pharmagreen Biotech Z Score vs. Beta Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pharmagreen Biotech's current stock value. Our valuation model uses many indicators to compare Pharmagreen Biotech value to that of its competitors to determine the firm's financial worth. Pharmagreen Biotech is rated below average in beta category among its peers. It is regarded second in z score category among its peers totaling about 3.12 of Z Score per Beta. Comparative valuation analysis is a catch-all model that can be used if you cannot value Pharmagreen Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pharmagreen Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Pharmagreen Z Score vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Pharmagreen Biotech |
| = | 1.44 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Pharmagreen Biotech |
| = | 4.5 |
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Pharmagreen Z Score Comparison
Pharmagreen Biotech is currently under evaluation in z score category among its peers.
Beta Analysis
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pharmagreen Biotech will likely underperform.
Pharmagreen Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pharmagreen Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pharmagreen Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Pharmagreen Biotech's change in net profit over the period of time. It can combine multiple indicators of Pharmagreen Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada. Pharmagreen Biotech is traded on OTC Exchange in the United States.
Pharmagreen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pharmagreen Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pharmagreen Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pharmagreen Biotech's important profitability drivers and their relationship over time.
Use Pharmagreen Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharmagreen Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharmagreen Biotech will appreciate offsetting losses from the drop in the long position's value.Pharmagreen Biotech Pair Trading
Pharmagreen Biotech Pair Trading Analysis
The ability to find closely correlated positions to Pharmagreen Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharmagreen Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharmagreen Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharmagreen Biotech to buy it.
The correlation of Pharmagreen Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharmagreen Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharmagreen Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharmagreen Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pharmagreen Biotech position
In addition to having Pharmagreen Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Cap ETFs Thematic Idea Now
Small Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 167 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Pharmagreen Pink Sheet
To fully project Pharmagreen Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pharmagreen Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pharmagreen Biotech's income statement, its balance sheet, and the statement of cash flows.